Schlag P, Dörsam J, Aguiar J L, Bartkowski R, Berger M
Department of Surgery, University of Heidelberg, F.R.G.
Eur J Cancer Clin Oncol. 1988 Jun;24(6):1013-8. doi: 10.1016/0277-5379(88)90151-4.
To evaluate the best locoregional approach in the treatment of hepatic tumors we investigated four different treatment modalities. Sixty female Sprague-Dawley rats were randomized to the following treatment groups: (1) untreated control; (2) hepatic artery ligation; (3) hepatic artery ligation plus portal 5-FU chemotherapy; (4) arterial 5-FU chemotherapy; (5) portal 5-FU chemotherapy. All animals received Novikoff hepatoma cells inoculated in the median liver lobe. After tumor inoculation animals were treated according to their randomization and surgery was performed for repeated tumor size measurements. Through hepatic artery ligation, hepatic artery ligation plus portal 5-FU infusion as well as through arterial 5-FU infusion a significant tumor growth inhibition compared to the untreated control could be achieved. The portal infusion group even showed an accelerated tumor growth; however, this effect was not significant. We conclude that the intraarterial application in terms of clinical feasibility and duration of response should be the preferred approach in locoregional therapy of liver malignancies.
为评估治疗肝肿瘤的最佳局部区域治疗方法,我们研究了四种不同的治疗方式。将60只雌性Sprague-Dawley大鼠随机分为以下治疗组:(1)未治疗对照组;(2)肝动脉结扎术;(3)肝动脉结扎术加门静脉5-氟尿嘧啶化疗;(4)动脉内5-氟尿嘧啶化疗;(5)门静脉5-氟尿嘧啶化疗。所有动物均在肝中叶接种Novikoff肝癌细胞。接种肿瘤后,动物根据随机分组进行治疗,并进行手术以重复测量肿瘤大小。通过肝动脉结扎术、肝动脉结扎术加门静脉5-氟尿嘧啶输注以及动脉内5-氟尿嘧啶输注,与未治疗对照组相比,可实现显著的肿瘤生长抑制。门静脉输注组甚至显示肿瘤生长加速;然而,这种效应并不显著。我们得出结论,就临床可行性和反应持续时间而言,动脉内应用应是肝恶性肿瘤局部区域治疗的首选方法。